OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2026.15473 OL-31-4-15473 Corrigendum [Corrigendum] Efficacy of transarterial chemoembolization-hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy in hepatocellular carcinoma with portal vein tumor thrombosis HouXunbo XuQiannan YinLinan WangHuiwen WuJuan LiuBowen HeDongfeng LiuRuibao 042026 28012026 31 4 120 Copyright: © 2026 Hou et al. 2026 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.

Oncol Lett 30: 363, 2025; DOI: 10.3892/ol.2025.15109

Subsequently to the publication of the above paper, the authors have contacted the Editrial Office to explain that, due to an inadvertent file upload error made during the submission process, Table I contained incorrect data regarding treatment-related adverse events in Group 1 (n=16 patients). The corrected version of Table I is shown on the next two pages, and the correct data for the Treatment-related adverse events in Group 1 column are highlighted in bold.

As a result of the inclusion of the incorrect data in Table I, the corresponding paragraph in the Results section (p. 3, the right-hand column) also contained inaccuracies. The text starting from line 36 should have as follows: “Treatment-related adverse events (AEs) were significantly more frequent and severe in Group 1 compared with the other groups (all P<0.001). In Group 1 (n=16), the most common adverse events included nausea and vomiting (14 patients, 87.5%), weight loss (13 patients, 81.2%), abdominal pain (12 patients, 75.0%), decreased appetite (12 patients, 75.0%), diarrhea (11 patients, 68.8%), rash (11 patients, 68.8%), fatigue (9 patients, 56.2%), hand-foot syndrome (6 patients, 37.5%), immune-related pneumonitis (5 patients, 31.2%), and hemorrhagic (bleeding) events (5 patients, 31.2%). Oral mucositis occurred in 7 patients (43.8%). No treatment-related deaths were observed in any group.”

Finally, the authors requested that an update be made to the corresponding author's email address for long-term academic correspondence. Although the originally listed email (ruibaoliu111@sina.com) remains active, Dr Ruibao Liu now uses liu_ruibao@sina.com as his primary and stable professional contact address, and the authors request that this email address should be used for all professional correspondence in the future.

Note that all the other data in the manuscript, including the baseline characteristics (for example, ascites, hepatitis C status and tumor burden), laboratory values, survival outcomes and statistical conclusions remain accurate and unchanged. The authors wished to confirm that the main findings and clinical implications of the study are unaffected by the errors that were made in Table I. The authors regret that these errors went unnoticed prior to the publication of this paper, and apologize to the readership for any inconvenience caused.

Clinical information of patients with hepatocellular carcinoma in the four treatment groups.

Characteristic Group 1 Group 2 Group 3 Group 4 P-value Between-group variations
Age, years 53.38±7.24 54.07±10.02 57.49±8.59 53.58±9.35 0.024 NS
Sex, n (%) 0.018 NS
  Male 15 (93.75) 77 (85.6) 87 (85.3) 28 (65.12)
  Female 1 (6.25) 13 (14.4) 15 (14.7) 15 (34.88)
Preoperative indices
  AST, U/l 54.00 52.00 53.00 54.00 0.926 NS
(42.25, 102.50) (35.50, 91.50) (38.00, 82.25) (39.00, 83.00)
  ALT, U/l 40.50 35.00 36.50 37.00 0.955 NS
(25.00, 53.25) (26.00, 63.00) (24.00, 57.75) (26.00, 52.00)
  TB, µmol/l 20.30 20.40 20.35 20.10 0.961 NS
(13.40, 26.25) (13.90, 26.60) (13.68, 28.38) (16.90, 28.10)
  PT, sec 12.20 12.00 12.30 12.50 0.167 NS
(11.65, 12.88) (11.35, 12.95) (11.78, 13.00) (11.90, 13.10)
  Albumin, g/l 40.90 39.45 37.65 39.50 0.01 Group 2 vs. group 3, P=0.009
(36.93, 42.10) (35.80, 43.30) (34.28, 40.80) (36.00, 42.30)
Tumor count, n (%) <0.001 Group 1 vs. group 2, P=0.0047
  ≤3 6 (37.5) 5 (5.6) 96 (94.1) 27 (62.8)
  >3 10 (62.5) 85 (94.4) 6 (5.9) 16 (37.2)
Maximum tumor diameter, n (%) <0.001 Group 1 vs. group 2, P<0.001
  <100 mm 8 (50.0) 0 (0.0) 62 (60.8) 33 (76.7)
  ≥100 mm 8 (50.0) 90 (100.0) 40 (39.2) 10 (23.3)
Medical history, n (%)
  Hepatitis B 4 (25.0) 70 (77.8) 73 (71.6) 34 (79.1) <0.001 Group 1 vs. group 2, P<0.001
  Hepatitis C 15 (93.8) 4 (4.4) 15 (14.7) 3 (7.00) <0.001 Group 1 vs. group 2. P<0.001
  Cirrhosis 4 (25.0) 67 (74.4) 75 (73.5) 33 (76.7) <0.001 Group 1 vs. group 2, P<0.001
  Ascites 13 (81.3) 18 (20.0) 34 (33.3) 2 (4.7) <0.001 Group 1 vs. group 2, P<0.001
ECOG, n (%) 0.285 NS
  <1 12 (75.0) 51 (56.7) 51 (50.0) 32 (74.4)
  ≥1 4 (25.0) 39 (43.3) 51 (50.0) 11 (25.6)
Child-Pugh classification <0.001 Group 2 vs. group 3, P<0.001
  A 14 (87.5) 90 (100.0) 80 (78.4) 39 (90.7)
  B 2 (12.5) 0 (0.0) 22 (21.6) 4 (9.3)
Pre-treatment AFP, n (%) 0.299 NS
  <400 ng/ml 7 (43.8) 46 (51.1) 54 (52.9) 16 (38.1)
  ≥400 ng/ml 9 (56.2) 44 (48.9) 48 (47.1) 27 (61.9)
Treatment-associated adverse events, n=16 (%)
  Fatigue 9 (56.2) 6 (6.7) 46 (45.1) 5 (11.6) <0.001 Group 1 vs. group 2, P<0.001
  Abdominal pain 12 (75.0) 0 (0.0) 42 (41.2) 2 (4.7) <0.001 Group 1 vs. group 2, P<0.001
  Diarrhea 11 (68.8) 7 (7.8) 39 (38.2) 2 (4.7) <0.001 Group 1 vs. group 2, P<0.001
  Nausea and vomiting 14 (87.5) 5 (5.6) 37 (36.3) 5 (11.6) <0.001 Group 1 vs. group 2, P<0.001
  Decreased appetite 12 (75.0) 7 (7.8) 42 (41.2) 8 (18.6) <0.001 Group 1 vs. group 2, P<0.001
  Weight loss 13 (81.2) 7 (7.8) 49 (48.0) 8 (18.6) <0.001 Group 1 vs. group 2, P<0.001
  Rash 11 (68.8) 8 (8.9) 26 (25.5) 0 (0.0) <0.001 Group 1 vs. group 2, P<0.001
  Oral mucositis 7 (43.8) 6 (6.7) 12 (11.8) 0 (0.0) <0.001 Group 1 vs. group 2, P<0.001
  Hand-foot syndrome 6 (37.5) 2 (2.2) 14 (13.7) 0 (0.0) <0.001 Group 1 vs. group 2, P<0.001
  Joint pain 8 (5.0) 2 (2.2) 9 (8.8) 0 (0.0) <0.001 Group 1 vs. group 2, P<0.001
  Bleeding events 5 (31.2) 4 (4.4) 30 (29.4) 0 (0.0) <0.001 Group 1 vs. group 2, P<0.001
  Immune-related pneumonitis 5 (31.2) 2 (2.2) 9 (8.8) 0 (0.0) <0.001 Group 1 vs. group 2, P<0.001

AST, aspartate aminotransferase; ALT, alanine aminotransferase; TB, total bilirubin; PT, prothrombin time; ECOG, Eastern Cooperative Oncology Group; AFP, α-fetoprotein; NS, no significance.